BR112017007194A2 - compostos de hidroxil purina e aplicações dos mesmos - Google Patents
compostos de hidroxil purina e aplicações dos mesmosInfo
- Publication number
- BR112017007194A2 BR112017007194A2 BR112017007194A BR112017007194A BR112017007194A2 BR 112017007194 A2 BR112017007194 A2 BR 112017007194A2 BR 112017007194 A BR112017007194 A BR 112017007194A BR 112017007194 A BR112017007194 A BR 112017007194A BR 112017007194 A2 BR112017007194 A2 BR 112017007194A2
- Authority
- BR
- Brazil
- Prior art keywords
- purine
- applications
- hydroxyl compounds
- hydroxyl
- pde2
- Prior art date
Links
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 title abstract 2
- 101100135859 Dictyostelium discoideum regA gene Proteins 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/14—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with two methyl radicals in positions 1 and 3 and two methyl radicals in positions 7, 8, or 9
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
compostos de hidroxil purina representados pela fórmula (i), tautômeros ou sais farmaceuticamente aceitáveis dos mesmos, e aplicações dos mesmos como inibidores de pde2 ou tnf-a.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410529928.9A CN105566324B (zh) | 2014-10-09 | 2014-10-09 | 羟基嘌呤类化合物及其应用 |
CN201410529928.9 | 2014-10-09 | ||
CN201510590904.9 | 2015-09-16 | ||
CN201510590904 | 2015-09-16 | ||
PCT/CN2015/090294 WO2016054971A1 (zh) | 2014-10-09 | 2015-09-22 | 羟基嘌呤类化合物及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112017007194A2 true BR112017007194A2 (pt) | 2017-12-26 |
BR112017007194B1 BR112017007194B1 (pt) | 2023-11-07 |
Family
ID=55652577
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017007194-0A BR112017007194B1 (pt) | 2014-10-09 | 2015-09-22 | Compostos de hidroxil purina e uso dos mesmos |
Country Status (15)
Country | Link |
---|---|
US (2) | US10098885B2 (pt) |
EP (1) | EP3205652B1 (pt) |
JP (1) | JP6527948B2 (pt) |
KR (1) | KR101997592B1 (pt) |
CN (1) | CN107001371B (pt) |
AU (1) | AU2015330490B2 (pt) |
BR (1) | BR112017007194B1 (pt) |
CA (1) | CA2964018C (pt) |
IL (1) | IL251659B (pt) |
MX (1) | MX2017004655A (pt) |
NZ (1) | NZ731344A (pt) |
RU (1) | RU2673458C1 (pt) |
SG (1) | SG11201702900SA (pt) |
TW (1) | TWI689511B (pt) |
WO (1) | WO2016054971A1 (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2964018C (en) | 2014-10-09 | 2019-04-02 | Guangdong Zhongsheng Pharmaceutical Co., Ltd | Hydroxyl purine compounds and applications thereof |
CN107614501B (zh) * | 2015-05-20 | 2020-01-14 | 广东众生睿创生物科技有限公司 | 羟基嘌呤类化合物及其应用 |
US10278973B2 (en) | 2015-05-20 | 2019-05-07 | Guangdong Raynovent Biotech Co., Ltd. | Hydroxyl purine compounds and use thereof |
WO2017071607A1 (zh) * | 2015-10-29 | 2017-05-04 | 南京明德新药研发股份有限公司 | 4H-吡唑并[1,5-α]苯并咪唑类化合物晶型及其制备方法和中间体 |
CN113717170A (zh) | 2016-04-01 | 2021-11-30 | 里科瑞尔姆Ip控股有限责任公司 | 雌激素受体调节剂 |
JP2019014656A (ja) * | 2017-07-03 | 2019-01-31 | 宇部興産株式会社 | プリン誘導体化合物及びプリン誘導体化合物変性共役ジエン重合体 |
CA3148221A1 (en) | 2019-08-06 | 2021-02-11 | Recurium Ip Holdings, Llc | Estrogen receptor modulators for treating mutants |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5426349B2 (pt) | 1973-10-26 | 1979-09-03 | ||
JPS601542B2 (ja) * | 1977-05-18 | 1985-01-16 | ダイキン工業株式会社 | 吸収式蓄熱冷暖房装置 |
JPS55118488A (en) * | 1979-03-05 | 1980-09-11 | Eisai Co Ltd | Theobromine derivative and its preparation |
DE3421072A1 (de) * | 1984-06-06 | 1985-12-12 | Heinrich Mack Nachf., 7918 Illertissen | 1,4:3,6-dianhydro-hexit-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
US5321029A (en) | 1988-11-14 | 1994-06-14 | Beecham-Wuelfing Gmbh & Co.K.G. | Xanthines |
IL100088A (en) | 1990-11-21 | 1995-07-31 | Smithkline Beecham Corp | FNT inhibitor preparations containing histogenic transducts converted at positions 1, 3, and 8 |
US5580873A (en) | 1992-03-04 | 1996-12-03 | Cell Therapeutics, Inc. | Enatiomerically pure hydroxylated xanthine compounds to treat proliferative vascular diseases |
DE69332634T2 (de) * | 1992-03-04 | 2003-05-08 | Cell Therapeutics Inc | Enantiomere hydroxylierte xanthinverbindungen |
US5780476A (en) * | 1992-11-16 | 1998-07-14 | Cell Therapeutics, Inc. | Hydroxyl-containing xanthine compounds |
EP0746557A4 (en) | 1994-02-18 | 1997-05-02 | Cell Therapeutics Inc | INTRACELLULAR SIGNALING MEDIATORS |
US6323201B1 (en) | 1994-12-29 | 2001-11-27 | The Regents Of The University Of California | Compounds for inhibition of ceramide-mediated signal transduction |
US5775205A (en) * | 1996-12-16 | 1998-07-07 | Melton; Bruce W. | Infuser unit for beverages |
ATE234099T1 (de) * | 1998-04-24 | 2003-03-15 | Leuven K U Res & Dev | Immununterdrückende effekte von 8 substituierten xanthinderivaten |
WO2000007541A2 (de) * | 1998-07-31 | 2000-02-17 | Aventis Pharma Deutschland Gmbh | Verwendung von xanthinderivaten zur behandlung von erektionsstörungen |
TWI347845B (en) * | 2002-03-06 | 2011-09-01 | Nycomed Gmbh | Pharmaceutical compositions,combinations,and kits for the treatment of respiratory diseases and use of the same |
WO2006104870A2 (en) | 2005-03-25 | 2006-10-05 | Schering Corporation | Methods of treating benign prostatic hyperplasia or lower urinary track symptoms by using pde 5 inhibitors |
US8207175B2 (en) | 2005-06-21 | 2012-06-26 | University Court Of The University Of Dundee | Inhibitor compounds |
US20110053961A1 (en) | 2009-02-27 | 2011-03-03 | Concert Pharmaceuticals, Inc. | Substituted xanthine derivatives |
US20140296263A1 (en) * | 2011-07-19 | 2014-10-02 | Concert Pharmaceuticals, Inc. | Substituted xanthine derivatives |
AU2012329274B2 (en) * | 2011-10-27 | 2016-11-10 | Protamed, Inc. | Caffeinated compounds and compositions for treatment of amyloid diseases and synucleinopathies |
CN102603737B (zh) * | 2012-02-17 | 2014-04-09 | 四川大学 | 吡啶并嘧啶酮类衍生物以及在制备抗肿瘤药物方面的用途 |
CN105566324B (zh) | 2014-10-09 | 2020-04-03 | 广东众生睿创生物科技有限公司 | 羟基嘌呤类化合物及其应用 |
CA2964018C (en) | 2014-10-09 | 2019-04-02 | Guangdong Zhongsheng Pharmaceutical Co., Ltd | Hydroxyl purine compounds and applications thereof |
WO2017071607A1 (zh) * | 2015-10-29 | 2017-05-04 | 南京明德新药研发股份有限公司 | 4H-吡唑并[1,5-α]苯并咪唑类化合物晶型及其制备方法和中间体 |
-
2015
- 2015-09-22 CA CA2964018A patent/CA2964018C/en active Active
- 2015-09-22 SG SG11201702900SA patent/SG11201702900SA/en unknown
- 2015-09-22 EP EP15848312.3A patent/EP3205652B1/en active Active
- 2015-09-22 BR BR112017007194-0A patent/BR112017007194B1/pt active IP Right Grant
- 2015-09-22 JP JP2017538284A patent/JP6527948B2/ja active Active
- 2015-09-22 NZ NZ731344A patent/NZ731344A/en unknown
- 2015-09-22 RU RU2017116164A patent/RU2673458C1/ru active
- 2015-09-22 KR KR1020177012407A patent/KR101997592B1/ko active IP Right Grant
- 2015-09-22 US US15/517,951 patent/US10098885B2/en not_active Ceased
- 2015-09-22 US US16/795,419 patent/USRE49128E1/en active Active
- 2015-09-22 CN CN201580054840.9A patent/CN107001371B/zh active Active
- 2015-09-22 AU AU2015330490A patent/AU2015330490B2/en active Active
- 2015-09-22 WO PCT/CN2015/090294 patent/WO2016054971A1/zh active Application Filing
- 2015-09-22 MX MX2017004655A patent/MX2017004655A/es unknown
- 2015-10-05 TW TW104132712A patent/TWI689511B/zh active
-
2017
- 2017-04-09 IL IL251659A patent/IL251659B/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
US10098885B2 (en) | 2018-10-16 |
TWI689511B (zh) | 2020-04-01 |
CN107001371B (zh) | 2019-07-05 |
AU2015330490A1 (en) | 2017-05-18 |
MX2017004655A (es) | 2018-03-27 |
JP2017531695A (ja) | 2017-10-26 |
EP3205652A4 (en) | 2017-08-16 |
USRE49128E1 (en) | 2022-07-12 |
BR112017007194B1 (pt) | 2023-11-07 |
JP6527948B2 (ja) | 2019-06-12 |
SG11201702900SA (en) | 2017-05-30 |
CA2964018C (en) | 2019-04-02 |
TW201619160A (zh) | 2016-06-01 |
AU2015330490B2 (en) | 2018-08-09 |
KR20170066588A (ko) | 2017-06-14 |
EP3205652A1 (en) | 2017-08-16 |
EP3205652B1 (en) | 2022-03-09 |
IL251659A0 (en) | 2017-06-29 |
NZ731344A (en) | 2018-08-31 |
CN107001371A (zh) | 2017-08-01 |
RU2673458C1 (ru) | 2018-11-27 |
WO2016054971A1 (zh) | 2016-04-14 |
CA2964018A1 (en) | 2016-04-14 |
KR101997592B1 (ko) | 2019-07-08 |
US20170326149A1 (en) | 2017-11-16 |
IL251659B (en) | 2021-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2017000078A (es) | Indazoles sustituidos con bencilo como inhibidores de bub1. | |
CL2016002394A1 (es) | Derivados de quinolina como inhibidores de smo | |
BR112017007194A2 (pt) | compostos de hidroxil purina e aplicações dos mesmos | |
CL2016003398A1 (es) | Compuestos de heteroarilo útiles como inhibidores de enzima activadora de sumo. | |
EA201692338A1 (ru) | Соединения 5-хлор-дифторметоксифенил-пиразолопиримидина, представляющие собой ингибиторы янус-киназы | |
EA201891024A1 (ru) | Соединения-ингибиторы tank-связывающей киназы | |
PH12017500207A1 (en) | Indoles for use in influenza virus infection | |
BR112017006305A2 (pt) | compostos heteroarila como inibidores de btk e usos dos mesmos | |
EA201692203A1 (ru) | Соединения, ингибирующие tank-связывающую киназу | |
EA201692219A1 (ru) | Способы получения противовирусных соединений | |
PH12017500393A1 (en) | Pyrrolopyrimidines for use in influenza virus infection | |
EA201690098A1 (ru) | Конденсированные трициклические соединения мочевины в качестве ингибиторов киназы raf и/или димера киназы raf | |
EA201790395A1 (ru) | Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы | |
CL2018000649A1 (es) | Nuevos compuestos bicíclicos como inhibidores duales de atx / ca | |
BR112017005266A2 (pt) | inibidores de mk2 e uso dos mesmos | |
UY34654A (es) | Inhibidores de la beta-secretasa | |
EA201692143A1 (ru) | Производные аминопиразина в качестве ингибиторов фосфатидилинозитол-3-киназы | |
EA201500801A1 (ru) | Бензохинолоновые ингибиторы vmat2 | |
UY35274A (es) | Compuestos y métodos para tratar infecciones bacterianas | |
EA201891666A1 (ru) | Арилзамещенные пиримидины для применения при инфекции, вызванной вирусом гриппа | |
BR112017028549A2 (pt) | derivados de pirimidina como inibidores de btk e usos dos mesmos | |
EA201692358A1 (ru) | Производные изоиндолина для применения в лечении вирусной инфекции | |
EA201791530A1 (ru) | НОВЫЕ N-АЦИЛАРИЛСУЛЬФОНАМИДНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ АМИНОАЦИЛ-тРНК СИНТЕТАЗЫ | |
EA201790687A1 (ru) | Хинолинкарбоксамиды для применения в лечении множественной миеломы | |
CL2016001488A1 (es) | Quinazolin-thf-aminas como inhibidores de pde1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B25A | Requested transfer of rights approved |
Owner name: MEDSHINE DISCOVERY INC. (CN) ; GUANGDONG RAYNOVENT BIOTECH CO., LTD. (CN) |
|
B25A | Requested transfer of rights approved |
Owner name: GUANGDONG RAYNOVENT BIOTECH CO., LTD. (CN) |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B25G | Requested change of headquarter approved |
Owner name: GUANGDONG RAYNOVENT BIOTECH CO., LTD. (CN) |
|
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/09/2015, OBSERVADAS AS CONDICOES LEGAIS |